Skip to content

Study · Case report or series · n = 1 · 2026

5 results

Semaglutide as a potential tool in pre-lung transplant weight loss optimization.

Ali R, Keyt H, Solis-Herrera C, Escobar-Vasco M

JCEM case reports1 Apr 2026

PMID41928866 (opens in a new tab)PMCIDPMC13043148 (opens in a new tab)DOI10.1210/jcemcr/luag040 (opens in a new tab)PepBankPUB-41928866
Download PDFPubMedAsk about this study
Jump to 5 results

Summary

Patients with end-stage lung disease go through an extensive screening process prior to transplant. Obesity and uncontrolled type 2 diabetes mellitus (T2DM) are unfavorable risk factors that lead to poor outcomes. We present the case of a 69-year-old man with stage IV chronic obstructive pulmonary disease (COPD) on chronic oxygen, T2DM on insulin, and class II obesity (reference range, body mass index [BMI], 35.0-39.9) who underwent pre-lung transplant evaluation. He had a BMI of 38.05, surpassing the institutional transplant eligibility criteria of BMI <32. The patient was initiated on semaglutide for weight loss. After 6 months, the patient's BMI decreased to 30.5, losing 25 kg and qualifying him for transplant. However, given substantial improvements in respiratory status, the pre-lung transplant committee deferred waitlisting. After 16 months of treatment, the patient lost a total of 35.17 kg, his forced vital capacity improved from 44% to 82%, and he was weaned off oxygen. Chronic hypoxia and corticosteroids make weight management challenging for COPD patients. This case demonstrates the use of semaglutide for rapid weight loss and improved respiratory function in patients with end-stage lung disease, emphasizing its emerging potential in pre-lung transplant optimization.
CC BYText from Europe PMC. Highlighted sentences are the source of results.

Results from this study5

5 results from studies that gave the peptide. 5 results from people.

  1. 01HumanCase report or seriesEfficacy outcome

    In a man with end-stage COPD and obesity, BMI decreased to 30.5 after 6 months of semaglutide.

    In plain wordsIn one man with severe lung disease and obesity, BMI fell to 30.5 after 6 months of semaglutide.

    Peptide
    Semaglutide
    Outcome
    DecreaseBMI after 6 months
    Study

    n = 1

    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    Dose not stated · 6 monthsAs given in this study (human).

    Measurements

    BMI
    30.5 kg/m2
    6 months
    BMI
    38.05 kg/m2
    baseline

    Source sentences

    Summary
    After 6 months, the patient's BMI decreased to 30.5
    2 context sentences
    Summary · context
    He had a BMI of 38.05, surpassing the institutional transplant eligibility criteria of BMI <32.
    Summary · context
    We present the case of a 69-year-old man with stage IV chronic obstructive pulmonary disease (COPD) on chronic oxygen, T2DM on insulin, and class II obesity (reference range, body mass index [BMI], 35.0-39.9) who underwent pre-lung transplant evaluation.
  2. 02HumanCase report or seriesEfficacy outcome

    In a man with end-stage COPD and obesity, semaglutide produced a weight loss of 25 kg after 6 months.

    In plain wordsIn one man with severe lung disease and obesity, semaglutide led to a 25 kg weight loss in 6 months.

    Peptide
    Semaglutide
    Outcome
    DecreaseWeight loss after 6 months
    Study

    n = 1

    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    Dose not stated · 6 monthsAs given in this study (human).

    Measurements

    Weight loss
    25 kg
    6 months

    Source sentences

    Summary
    losing 25 kg and qualifying him for transplant.
    1 context sentence
    Summary · context
    We present the case of a 69-year-old man with stage IV chronic obstructive pulmonary disease (COPD) on chronic oxygen, T2DM on insulin, and class II obesity (reference range, body mass index [BMI], 35.0-39.9) who underwent pre-lung transplant evaluation.
  3. 03HumanCase report or seriesEfficacy outcome

    In a man with end-stage COPD and obesity, total weight loss was 35.17 kg after 16 months of semaglutide.

    In plain wordsIn one man with severe lung disease and obesity, total weight loss reached 35.17 kg after 16 months of semaglutide.

    Peptide
    Semaglutide
    Outcome
    DecreaseTotal weight loss after 16 months
    Study

    n = 1

    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    Dose not stated · 16 monthsAs given in this study (human).

    Measurements

    Weight loss
    35.17 kg
    16 months

    Source sentences

    Summary
    After 16 months of treatment, the patient lost a total of 35.17 kg
    1 context sentence
    Summary · context
    We present the case of a 69-year-old man with stage IV chronic obstructive pulmonary disease (COPD) on chronic oxygen, T2DM on insulin, and class II obesity (reference range, body mass index [BMI], 35.0-39.9) who underwent pre-lung transplant evaluation.
  4. 04HumanCase report or seriesEfficacy outcome

    In a man with end-stage COPD and obesity, forced vital capacity improved from 44% to 82% after 16 months of semaglutide.

    In plain wordsIn one man with severe lung disease and obesity, lung capacity rose from 44% to 82% after 16 months of semaglutide.

    Peptide
    Semaglutide
    Outcome
    IncreaseForced vital capacity
    Study

    n = 1

    Outcome group
    Respiratory function · Respiratory
    Studied dose
    Dose not stated · 16 monthsAs given in this study (human).

    Measurements

    Forced vital capacity
    44%
    baseline
    Forced vital capacity
    82%
    16 months

    Source sentences

    Summary
    his forced vital capacity improved from 44% to 82%
    1 context sentence
    Summary · context
    We present the case of a 69-year-old man with stage IV chronic obstructive pulmonary disease (COPD) on chronic oxygen, T2DM on insulin, and class II obesity (reference range, body mass index [BMI], 35.0-39.9) who underwent pre-lung transplant evaluation.
  5. 05HumanCase report or seriesEfficacy outcome

    In a man with end-stage COPD and obesity on chronic oxygen, he was weaned off oxygen after 16 months of semaglutide.

    In plain wordsIn one man with severe lung disease and obesity, he no longer needed oxygen after 16 months of semaglutide.

    Peptide
    Semaglutide
    Outcome
    DecreaseChronic oxygen requirement
    Study

    n = 1

    Outcome group
    Respiratory function · Respiratory
    Studied dose
    Dose not stated · 16 monthsAs given in this study (human).

    Source sentences

    Summary
    and he was weaned off oxygen.
    1 context sentence
    Summary · context
    We present the case of a 69-year-old man with stage IV chronic obstructive pulmonary disease (COPD) on chronic oxygen, T2DM on insulin, and class II obesity (reference range, body mass index [BMI], 35.0-39.9) who underwent pre-lung transplant evaluation.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    11 Oct 2026, 00:04 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:06 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.